Revolutionizing Weight problems and Diabetes Remedy: Kyung Hee Medical Analysis Institute Companions with Progen and ODN for Progressive Options
The fight against obesity and diabetes has taken a significant leap forward with the recent partnership between Kyung Hee Medical Research Institute, Progen, and ODN. This tripartite agreement aims to develop breakthrough treatments for these pervasive health conditions.
Progen, known for its innovative approach to tackling obesity and diabetes, joins forces with ODN, a digital therapeutics startup that emerged from the Kyunghee Digital Health Center. The collaboration underscores a shared commitment to advancing medical research and offering novel therapeutic solutions.
The strategic partnership is set to:
- Formulate and implement research strategies to pioneer next-generation treatments for obesity and diabetes.
- Design clinical protocols for evaluating treatment efficacy in patients with severe obesity.
- Collect and assess efficacy and safety data in this patient demographic.
- Explore the potential of digital therapeutic devices in managing chronic diseases among the severely obese through an advanced digital disease management platform.
Director Kyung-Sik Yoon of the Kyung Hee Medical Research Institute expressed optimism about the memorandum of understanding, highlighting its potential to uncover optimal treatments for patients suffering from obesity and diabetes. “Leveraging our institute’s extensive research capabilities and robust data infrastructure, we are committed to supporting this initiative fully,” he stated.
Progen’s CEO, Kim Jonng-gyun, shed light on their drug, PG-102, a pioneering dual agonist medication targeting GLP-1 and GLP-2 receptors. Designed for monthly injections and weekly oral administration, PG-102 recently received approval to enter a Phase 2 clinical trial for obese and diabetic patients. “This collaboration aims to expand the range of effective treatment options available for individuals grappling with severe obesity,” explained Kim.
Lee Sang-yeol, CEO of ODN and Professor of Endocrinology at Kyung Hee University Hospital, shared his vision for the project. “Our mission is to enhance the health and quality of life for those living with obesity and diabetes through AI-driven personalized digital therapeutic devices, grounded in scientific research and cutting-edge technology,” he remarked. Lee is particularly excited about the potential for this collaboration with Progen to usher in a new era of digital convergence in medicine.
This partnership marks a significant milestone in the journey towards combating obesity and diabetes. By combining expertise in medical research, innovative drug development, and digital therapeutics, Kyung Hee Medical Research Institute, Progen, and ODN set the stage for ground-breaking advancements in treatment and patient care. The collaborative effort is a beacon of hope for millions worldwide, promising a future where these chronic conditions can be managed more effectively and compassionately.
